solely attributed to dopamine modulation, and recent in vitro binding studies showed highest affinity of pridopidine to the sigma-1 receptor. These new preclinical observations in conjunction with efficacy and tolerability results from the recently completed large phase II, 52-week, hypothesis-generating study (PRIDE-HD) provide new insights into the therapeutic potential of pridopidine, not limited to modulation of dopaminergic pathways.
Poster 3 Effect of Pridopidine on Functional Capacity of Patients with Huntington Disease

Summary
The Total Functional Capacity (TFC) scale evaluates the capacity of patients with Huntington disease to work, handle finances and domestic chores, perform activities of daily living, and live independently; it is most sensitive to early changes in disability. The results of this exploratory analysis suggest that TFC decline is slower over time in patients who received pridopidine in OPEN-HART compared with those who received placebo in the CARE-HD and 2CARE studies.
Poster 4 Clinical Development of VX15 Anti-Semaphorin 4D Antibody as a Potential Treatment for Huntington Disease
Summary
The SIGNAL trial experience to date has shown that recruitment into this first study of a biologic administered intravenously to patients with late prodromal and early manifest HD is feasible and that participant retention and compliance with the study protocol has compared favorably with prior experience in other HD studies. A prespecified interim analysis of data from 6 months of double-blind treatment with VX15/2503 or placebo (cohort A) was completed in August 2016 and no concerning safety signals were identified; additional study results will be shared as they become available.
Poster 5 Industry Collaborations in Clinical Trial Development: Leveraging In-Person Patient and Caregiver Input in HD
Summary
Raptor Pharmaceuticals Inc. partnered with the Huntington Study Group to obtain feedback from patients with Huntington disease (HD) and caregivers about clinical trials and its planned phase III program through a live in-person advisory board meeting. Recommendations on generally applicable logistics in clinical studies in HD (e.g., use of placebo controls, concomitant medications, number of study site visits, and assessments) were discussed and are presented here, highlighting the value of industry and patient and caregiver collaborations towards finalization of patient-friendly study protocols.
Poster 6
Oxcarbazepine for Irritability in Huntington Disease: A Case Series Summary This study examined the potential role of the medication, oxcarbazepine (Trileptal), for reducing irritability in patients with Huntington disease.
Poster 7 Safety and Tolerability of SRX246 in Irritable Patients with Huntington Disease (STAIR)
Summary STAIR is a randomized, placebo-controlled, double-blind 12-week study to assess the safety and tolerability of treatment with SRX246, a first-in-class vasopressin 1a receptor antagonist, as a novel therapeutic agent intended to ameliorate symptoms associated with irritability in symptomatic patients with HD, symptoms that can lead to negative actions and interactions and reduced quality of life for families living with HD.
Poster 8
Discovery and Early Clinical Development of the First Allele-Specific Stereopure Antisense Oligonucleotide Drug to Treat Huntington Disease Summary WAVE Life Sciences has developed proprietary technology enabling the synthesis of stereopure phosphorothioate (PS) antisense oligonucleotides in which stereochemistry at each PS position is precisely controlled. With this precise control, we are developing genetic medicines to selectively target the mutant form of huntingtin, leaving the healthy form relatively unaffected. The application of stereochemistry to PS oligonucleotide therapeutics for allele-specific silencing holds the promise of individualized, diseasemodifying treatments for hereditary neurological diseases such as Huntington disease.
Poster 9
Motor-Cognitive Dual-Task Deficits in Individuals with Early-to-Mid-Stage Huntington Disease
Summary
We evaluated simple and complex dual-task ability, or the ability to perform 2 tasks simultaneously (e.g., walking while talking) in 32 individuals with early-to-mid-stage Huntington disease (HD). We found that dual-task ability was impaired in individuals with HD and that poorer performance on the dual tasks was related to poorer cognitive performance, diseasespecific motor performance, functional ability, and the number of falls reported in the 6 months following testing. Dual-task measures may be useful in improving the prediction of falls risk in HD.
Poster 10 Trunk Sway Relates to Increased Fall Risk in Younger Individuals with Huntington Disease and to Gait and Mobility Measures
Summary Increased side-to-side and front-to-back sway of the body is related to walking and fall risk in individuals with Huntington disease. In addition, we found that falling was related to younger age.
Poster 11 Validation of the Step Test Evaluation of Performance on Stairs (STEPS) Assessment in Individuals with Huntington disease
Summary
The Step Test Evaluation of Performance on Stairs (STEPS) tool appears to be a potentially valid and reliable means with which to assess an individual's ability to climb stairs safely.
Poster 12
Using the Balance Tracking System (BTrackS™) to Measure Disease Progression and Fall Risk in Huntington Disease Summary This study was undertaken to see if we could use a simple body sway assessment device to measure balance in Huntington disease (HD). We found that we could, and that we could identify patients with HD at increased risk for falls using this brief balance test and a simple measure called the Timed Up and Go (TUG).
Poster 13
Functional Independence Measure Changes in Huntington Disease Post-Inpatient Rehabilitation
Summary
We reviewed the medical records of 50 consecutive people, admitted to our Huntington disease (HD) inpatient physical rehabilitation unit, from 2010 to 2011. There are preliminary data to suggest inpatient rehabilitation can improve day-today motor function for people living with HD.
Poster 14 Evaluating Wearable Sensors for Objective Measurement of Motor Features of HD-A Pilot Study
Summary Current measures of Huntington disease (HD) are subjective and rely on episodic in-person assessments. New technology, such as wearable sensors, have the potential to provide objective, sensitive assessments of motor features of HD in the clinic and at home. This pilot study evaluates the feasibility and value of such technologies in HD.
Poster 15
Understanding Patient-Reported Outcome Measures in Huntington Disease: At What Point is Cognitive Impairment Related to Poor Measurement Reliability? Summary As HD symptoms progress and cognition worsens, self-report measures should be considered in conjunction with other information when making clinical decisions. Our data provide evidence of cut-off points for when to rely on self-report measures and when other assessments of symptoms should be considered.
Summary A select group of psychiatry experts from the Huntington Study Group and European Huntington Disease Network with extensive experience in the care of Huntington disease (HD) have led this effort to develop clinical practice guides that can help other physicians when treating symptoms of HD. Many individuals with HD do not have access to specialty care. These guides are intended as information tools that can be used to inform families and to improve care provided by general physicians outside of centers. Guides for the management of 5 symptoms, including agitation, anxiety, apathy, psychosis, and sleep problems in HD will be presented.
Poster 19
Suicide Attempts and Huntington Disease: Perseveration, Not Just Impulsivity
Summary
Patients with Huntington disease (HD) attempt suicide at a higher rate than the general population, although the specific cognitive and behavioral risk factors for attempting suicide have not been fully elucidated. Based on a case series of 3 patients with HD who attempted suicide after ruminating on distressing thoughts, we suggest that perseverative negative thoughts may be associated with suicidal behavior in motor manifest patients.
Poster 20
Assessing the Severity of Depression and Suicidality Associated with Tetrabenazine Use: An Evaluation of the Enroll-HD Database Summary Tetrabenazine is a useful drug for the treatment of Huntington disease-related chorea, but it has been associated with higher incidences of depression and suicidality. This study was conducted to determine if there was a difference in the severity of depression and suicidal thoughts between patients that were taking tetrabenazine and those that were not. Our results show that tetrabenazine was not associated with more severe depression or suicidality.
Poster 21
Substance Abuse Leads to Earlier Age of Onset of Huntington Disease: An Epidemiological Study of the Enroll-HD Database
Summary
These results demonstrate that substances of abuse (alcohol, tobacco, and illicit drugs) can negatively affect patients with Huntington disease (HD). Specifically, patients with HD who used substances of abuse had an earlier age of motor onset than patients who did not abuse substances. 
The demands of clinical trials in Huntington disease (HD) are increasing. The Enroll-HD platform, which includes the Enroll-HD observational study of patients with HD, has over 135 active clinical sites and over 11,600 participants. The study database can be used to help identify potentially eligible participants for clinical trials. The Enroll-HD study team has good relationships with the HD study site staff and can help to support the set up and ongoing running of clinical trials. The Enroll-HD platform also has an online training website to help train study site staff in HD assessments.
Poster 25 Enroll-HD: Current Status
Summary Enroll-HD is a clinical research platform that includes an observational study of Huntington disease (HD). Eligible participants include individuals who are gene expansion carriers, individuals with unknown genotype, and controls. Data are collected annually on motor, cognitive, and behavioral symptoms, releasing coded data to researchers periodically. Enroll-HD provides high quality clinical data and biological samples. As a research platform, Enroll-HD brings together a novel set of tools for HD clinical research that is easily available for researchers.
Poster 26
Descriptive Analysis of Patients with Concurrent Huntington Disease and Multiple Sclerosis in the ENROLL-HD Prospective Registry Study Summary This project investigated the subset of patients with a cooccurrence of Huntington disease (HD) and multiple sclerosis (MS) within the ENROLL-HD database. Results indicate an expected sex ratio, overlapping symptoms between HD and MS, and a higher prevalence of MS in HD patients compared than in the general population.
Poster 27
Clinical and Imaging Markers of Psychiatric Features in Premanifest Huntington Disease Summary Psychiatric symptoms frequently occur in Huntington disease (HD), potentially even occurring early in its course. Our study examined psychiatric features and structural brain changes on magnetic resonance imaging (MRI) scans in a large group of patients with premanifest HD from the PREDICT-HD study. Compared with gene-negative patients, gene-positive, patients with premanifest HD had more psychiatric symptoms and changes on MRI scans in brain areas involved in mood and HD. Clinical and imaging markers may be helpful in the early identification and application of symptomatic or diseasemodifying treatments.
Poster 28
Developing a Disease-Specific Health Index for Huntington Disease
Summary
The University of Rochester is developing a quality-of-life measure for persons living with Huntington disease (HD). This measure may better capture in clinical trials the experience of persons living with HD.
Poster 29 A Pilot Study of the Interaction of a Biomarker of Inflammation and the Endocannabinoid System in Huntington Disease
Summary Huntington disease (HD) is associated with inflammation outside of the brain and increased levels of a marker of inflammation called interleukin (IL)-6 in the blood of individuals with HD. We evaluated how IL-6 affects levels of the endogenous cannabinoid in blood cells from individuals with HD and healthy controls. 
Poster 30
Summary
We studied in the functional connectivity between the motor cortex and the striatum in different stages of Huntington disease (HD) using functional magnetic resonance imaging. We assessed 34 people in different stages of HD and 16 healthy controls using high field strength (7 T) scanning. The analysis of data showed that there is a functional impairment of connections involved in motor control even in stages of HD when patients do not have symptoms. This may be a useful marker for future clinical trials.
Poster 33
Structural and Biochemical Analysis of Full-length Huntingtin and the Effect of the Polyglutamine Expansion
Summary
We reveal the molecular architecture of full-length huntingtin protein and show that polyglutamine expansion affects the structure and function of huntingtin.
Poster 34
Modulation of Brain Connectivity by Pridopidine Highlights Potentiality for Functional Magnetic Resonance Imaging Biomarkers
Summary
The function of neuronal brain connections may be measured by functional magnetic resonance imaging. We have analyzed longitudinal, short-term changes of functional connectivity in a clinically and genetically characterized Huntington disease cohort (n = 10) and found significant differences after treatment with pridopidine in 3 out of 4 treated patients.
Poster 35
Cross-Sectional and Longitudinal Analysis of Juvenile Huntington Disease in Italy Summary Juvenile Huntington disease frequency is likely underestimated because associated in most cases with atypical presentation other than movement disorder. Infantile onset is a rare variant caused by overexpanded mutations. Collection of biosamples from these rare patients may represent an important step to set up new laboratory models for in vitro analyses.
Poster 36
Huntington's in Australia: A Hidden History Summary Not much is known about the history of Huntington disease (HD) outside the UK and USA. This paper tells some of the often-hidden history of HD in Australia, beginning with transported convicts from the UK. First discoveries, the Tasmanian story, eugenics, and changes in the 1970s are discussed.
Poster 37 Attitudes Towards Gene Therapy in Huntington disease
Summary
Gene therapy research has begun for Huntington disease. We used a survey to assess the level of risk individuals will consider and their knowledge about the therapy. We feel that these factors should play a role in the development of clinical gene therapy trials.
Poster 38 Intermediate Allele Expansion Leads to Huntington Disease Expression in Large Kindred
Summary This is a case study to look at a larger expansion in a family where the paternal intermediate allele of 32 CAG repeats expanded in the next generation to an allele with 47 repeats. 
Poster 39
Summary
Over 30% of people with dementia continue to drive. There is a lack of standards to manage the risk of dementia-impaired driving. Appropriate guidelines to assess driving cessation in people with dementia would improve the overall evaluation and management of dementia-impaired driving for community professionals and social workers.
Poster 42
Quality Improvement in Healthcare for Huntington Disease Summary Improving the quality of healthcare for people with HD involves identifying and modifying the care factors that most concern patients, family members, and their healthcare providers. As partners, the Huntington disease family community and local expert providers can design a system that reduces the work of obtaining care, improves education and communication, and brings together the resources needed for solutions. Quality-improvement projects can improve the lives of people with HD now, while creating a local healthcare program capable of delivering the disease-modifying treatments of the future. 
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Abstract
Pridopidine, a small molecule in mid-stage clinical development for HD, demonstrated improvement of motor symptoms in the clinic, as well as in preclinical models, and was originally characterized as a dopaminergic stabilizer. The motor activity of pridopidine was mainly attributed to its low-affinity interaction with dopamine D2 receptors. However, the mechanism of action of pridopidine cannot be solely attributed to dopamine modulation, and recent in vitro binding studies showed highest affinity of pridopidine to the sigma-1 receptor (S1R). The S1R is a highly conserved transmembrane protein located in the endoplasmic reticulum (ER) membrane. It is specifically enriched in the ER subregion contacting mitochondria and acts as a ligand-activated chaperone that can modulate many cellular processes, including calcium-mediated ER stress, neuritogenesis, and cell differentiation. The expression and distribution of the S1R was found to be altered in several neurodegenerative diseases (NDDs), such as Alzheimer disease, Parkinson disease, and Huntington disease [1] . This makes S1R an attractive target for the treatment of neurodegenerative diseases [2, 3] . Further investigation of pridopidine activities reveals it enhances neuroprotective pathways which are impaired in NDDs. In in vitro studies, pridopidine stabilizes medium spiny neuron (MSN) spines in YAC128 corticostriatal co-cultures and enhances brain-derived neurotrophic factor (BDNF) secretion from rat neuroblastoma cells, activities mediated by activation of the S1R. In vivo, pridopidine activates neuroprotective gene expression pathways, including the BDNF, protein kinase B, and glucocorticoid receptor (GR) pathways, known to be impaired in NDDs [4] . These new preclinical observations in conjunction with efficacy and tolerability results from the recently completed large phase II, 52-week, hypothesis-generating study (PRIDE-HD) provide new insights into the therapeutic potential of pridopidine, not limited to modulation of dopaminergic pathways. Methods: This analysis compared the OPEN-HART cohort (n = 50) that received pridopidine 90 mg/day and the placebo cohorts of CARE-HD (n = 80) and 2CARE (n = 213) without matching baseline characteristics. This analysis used TFC scores at baseline, 12, 24, and 36 months from OPEN-HART and 2CARE; and TFC scores at baseline, 12, 25, and 30 months from CARE-HD. Results: At baseline, the OPEN-HART cohort had the lowest absolute mean (SD) TFC score compared with the CARE-HD and 2CARE cohorts [9.14 (2.78), 10.3 (1.7), and 11.05 (1.47), respectively]. The mean (SD) change from baseline in TFC at 12 months for OPEN-HART was: -0.49 (1.60); CARE-HD: -1.00 (1.48); and 2CARE: -1.11 (1.62); at 24 months (OPEN-HART and 2CARE) and 25 months (CARE-HD) was: -1.00 (1.92), -1.80 (2.06), and -2.24 (1.91), respectively; at 36 months (OPEN-HART and 2CARE) was: -1.68 (2.22) and -2.54 (2.53), respectively; and at 30 months (CARE-HD) was: 2.80 (2.27).
Conclusions: This exploratory analysis suggests that the TFC decline is slower over time in patients who received pridopidine in OPEN-HART compared with those who received placebo in CARE-HD and 2CARE studies. Limitations of comparing data across studies should be considered in interpreting these results. Additional work is warranted to confirm these findings, including analysis using matched cohorts and prospective clinical trials. Abstract Semaphorin 4D (SEMA4D) and its high-affinity receptor, Plexin B1 (PLXNB1), are expressed on brain neural, endothelial, and inflammatory cells. SEMA4D signaling through PLXNB1 triggers activation of inflammatory glial cells, inhibits migration and differentiation of oligodendrocyte precursor cells that can repair damage to white matter, and disrupts endothelial tight junctions that are required for the integrity of the blood-brain barrier (BBB). Chronic inflammation, neuronal degeneration, and disruption of the BBB are believed to play an important role in neuroinflammatory and neurodegenerative diseases. Vaccinex has demonstrated in several preclinical models, including Huntington disease (HD) transgenic mice, that antibody neutralization of SEMA4D ameliorates neurodegenerative processes by i) reducing damage associated with chronic activation of innate glial inflammatory cells; ii) promoting remyelination through survival, migration, and differentiation of oligodendrocyte precursors; and iii) preventing SEMA4D-mediated compromise of the BBB. Two phase I clinical trials of the investigational humanized anti-SEMA4D antibody VX15/2503 have been completed with safety and pharmacokinetic profiles that have supported continued development. The randomized double-blind SIGNAL phase II clinical trial enrolling patients with prodromal and early manifest HD treated with either VX15/2503 anti-SEMA4D antibody or matching placebo was initiated in July of 2015. This study has an adaptive design and will evaluate safety, tolerability, and efficacy of monthly intravenous administration of the investigational agent as reflected in clinical features of HD, including cognition (HD-CAB) and quantitative motor assessment, as well as changes in volumetric magnetic resonance imaging of defined brain regions. Positron emission tomography (PET) employing two ligands, fluorodeoxyglucose and PBR-28, is also employed to detect changes in regional brain metabolism and microglial activation, respectively. Enrollment of 36 subjects in cohort A was completed in December 2015; these patients received randomized treatment for the first 6 months and then will receive openlabel VX15/2503 for an additional 6 months. Enrollment of 53 participants in cohort B was completed in September 2016; these patients will receive randomized treatment with VX15 or placebo for a total of 18 months. The SIGNAL trial experience to date has shown that recruitment into this first study of a biologic administered intravenously to patients with late prodromal and early manifest HD is feasible and that participant retention and compliance with the study protocol has compared favorably with prior experience in other HD studies. A prespecified interim analysis of data from 6 months of double-blind treatment with VX15/2503 or placebo (cohort A) was completed in August 2016 and no concerning safety signals were identified; additional study results will be shared as they become available. Acknowledgments: Vaccinex is very appreciative of the participants in this study who are helping to investigate VX15/2503 as a potential treatment for HD. In addition, we wish to thank the Huntington Study Group 
Background:
In rare diseases such as Huntington disease (HD) where treatment options are limited, effective planning of randomized clinical trials and trial design could benefit from patient and caregiver real life experience and input. Raptor Pharmaceuticals and the Huntington Study Group (HSG), a not-for-profit global network of researchers, clinicians, advocacy groups, and families with expertise in HD, partnered to conduct a clinician-moderated, patient-centric advisory board, to share Raptor's phase III clinical trial plans for evaluating RP103 in HD and gather feedback from the patients and caregivers.
Methods: Twelve participants (7 patients, 5 caregivers) with varying degrees of clinical trial knowledge and representing a diverse group of adult-onset HD, identified and recruited by the HSG and Huntington's Disease Society of America, provided feedback through an online survey and live meeting. Impact of factors affecting clinical trial participation was measured according to the following rating choices: 1 = not important, 2 = somewhat important, 3 = important, and 4 = very important. Results: More than half of the participants endorsed an inability to remain on current therapy (67%) or the occurrence of side effects (58%) as important/very important barriers to any clinical trial participation, followed by the use of a placebo control (42%), distance from clinical study site (42%), travel logistics and expenses (42%), patient confidentiality (33%), distrust of research (8%), and time requirements (8%). In turn, to enhance patient recruitment and retention, the following were recommended by the participants: unrestricted access to tetrabenazine or equivalent medication, open-label extension period for placebo-controlled trials, transportation and lodging assistance, and periodic home healthcare visits or telephone calls from a nurse. Conclusions: Feedback can be effectively obtained from patients and caregivers through a live in-person forum, helping to identify solutions to participation barriers and benefiting industry collaboration towards finalization of clinical study protocols.
Poster 6
Oxcarbazepine for Irritability in Huntington Disease: A Case Series Glenn T. Konopaske, Robin Zingales-Browne, and Bonnie L. Hennig. UCONN Health, Farmington, CT, USA.
Abstract
Background: Irritability is a common and disabling neuropsychiatric manifestation of Huntington disease (HD). No medication has been approved for the management of irritability in HD. Oxcarbazepine has been shown to reduce irritability in patients with psychiatric disorders. In this study, we will seek to determine whether oxcarbazepine reduces irritability in community-dwelling patients with HD. Methods: A retrospective chart review will be conducted at the UConn Health HD Program. Patient charts will be reviewed to identify patients with HD previously treated with oxcarbazepine for at least 4 weeks for irritability. All patients will be community dwelling and have a verified HD genepositive status. Results: This study will describe clinical and demographic characteristics of patients in the UConn Health HD program previously treated with oxcarbazepine for irritability. Retrospective Clinical Global Impression (CGI)-Severity scores will be generated using medical records at time points before and after initiation of treatment with oxcarbazepine. Any clinical improvement will be assessed using the CGIImprovement scale. Concomintant psychotropic medications in addition to oxcarbazepine will also be reported. Conclusions: The small sample size and retrospective nature of this study will limit generalizability. Nevertheless, this study might indicate whether a definitive double-blind, placebo-controlled trial assessing the efficacy of oxcarbazepine for irritability for HD is warranted. Azevan Pharmaceuticals, Bethlehem, PA, USA.
The objective was to assess the safety and tolerability of 12 weeks of treatment with SRX246 in early symptomatic Huntington's disease (HD) with irritability and explore the use of instruments for measuring neuropsychiatric symptoms in patients with HD. Patients with HD commonly experience irritability, which can lead to negative actions and interactions, reduced quality of life for HD families, and polypharmacy of limited effectiveness. Patients often have a limited awareness of their symptoms and its significant adverse impact, especially on their families. STAIR is a 3-arm, multicenter, randomized, placebo-controlled, double-blind, 12-week dose-escalation study to assess the tolerability and safety of SRX246, a first-in-class vasopressin 1a receptor antagonist, as a novel therapeutic agent intended to ameliorate symptoms associated with irritability in symptomatic patients with HD. Exploratory objectives include assessments of the activity of SRX246 compared with placebo using measures of irritability, and the use of an electronic diary to prompt patients to take the study drug, and assess mood and behavior. Patients will be randomized to receive placebo, 120 mg, or 160 mg twice daily of SRX246 for a total of 12 weeks. Patients will have 5 inperson follow-up visits and 2 telephone visits during the 12-week study period. Each patient will have a study partner, who has contact with them at least 4 times per week, to assist with visits, taking study medication, and provide feedback about the patient's mood and behavior. Twenty-two NeuroNEXT Network centers across the USA are participating with the goal of randomizing 108 patients. The STAIR study is being conducted through the NeuroNEXT Network by the sponsor, Azevan Pharmaceuticals, Inc., through an Small Business Innovation Research fast-track award from the National Institute of Neurological Diseases and Stroke. Enrollment began in May 2016. This presentation will provide an update on the current progress of recruitment into the study. 
Huntington disease (HD) is a rare, progressive neurological disease that results in motor, cognitive, and psychiatric disability, and is invariably fatal. Because it is a genetic, hereditary disease, it can affect multiple members of a single family across generations. It is caused by known mutations on a single gene and is characterized by an expansion of a CAG triplet repeat in the huntingtin (HTT) gene. Current oligonucleotide based approaches target HTT leading to nonspecific lowering of both mutant and wild-type (healthy) huntingtin protein. As wild-type HTT protein is critical for brain (neuronal) development and functions, suppression of the mutant protein while maintaining wild-type HTT is desirable. WAVE Life Sciences has developed proprietary technology enabling the synthesis of stereopure phosphorothioate (PS) antisense oligonucleotides (ASOs) in which stereochemistry at each PS position is precisely controlled. With this precise control, we are developing genetic medicines to target selectively the mutant form of HTT, leaving the healthy form relatively unaffected. Our first candidate, WVE-120101, targets rs362307 single nucleotide polymorphism (SNP) associated with the mutant HTT. Further, observations from nonclinical studies in monkeys show that upon intrathecal administration, WVE-120101 is distributed via cerebrospinal fluid circulation to various areas of the brain affected by HD (where it is required for pharmacological action). Localization of the ASO is consistent with perinuclear distribution. We will present here the preclinical data and an overview of plans for screening and enrollment of patients carrying the SNP target for the first 2 allele-specific HD trials to begin in early 2017. Advanced stereochemistry with the ability to generate stereopure ASOs as therapies may allow a personalized, safe, and effective approach to the treatment of this devastating disease. The application of stereochemistry to PS oligonucleotide therapeutics for allele-specific silencing holds the promise of individualized, disease-modifying treatments for hereditary neurological diseases such as HD. Columbia University, New York, NY, USA.
Abstract Background: Huntington disease (HD) results in a range of cognitive and motor impairments that progress throughout the disease stages; however, little research has evaluated specific dual-task abilities in this population, and the degree to which they may be related to functional ability. Objectives: The purpose of this study was to 1) examine simple and complex motor-cognitive dual-task performance in individuals with HD; 2) determine relationships between dual-task walking ability and disease-specific measures of motor, cognitive, and functional ability; and 3) examine the relationship of dual-task measures to falls in individuals with HD.
Methods: Thirty-two individuals with HD were evaluated for simple and complex dual-task ability using the Walking While Talking Test. Demographics and diseasespecific measures of motor, cognitive, and functional ability were also obtained. Results: Individuals with HD had impairments in simple and complex dual-task ability. Simple dual-task walking was correlated to disease-specific motor scores, as well as cognitive performance, but complex dual-task walking was correlated with total functional capacity, as well as a range of cognitive measures. Number of prospective falls was moderately-tostrongly correlated to dual-task measures. Conclusions: Our results suggest that individuals with HD have impairments in cognitive-motor dual-task ability that are related to disease progression and specifically functional ability. Dual-task measures appear to evaluate a unique construct in individuals with early to mid-stage HD, and may have value in improving the prediction of falls risk in this population. Results: Multiple stepwise linear regression analysis showed that age was negatively correlated with reported falls, with falls being associated with younger age (r = -0.44, p = 0.004) and increased posterior pelvic tilt in standing (r = 0.54, p = 0.033). Disease severity as rated by the Unified Huntington Disease Rating Scale was explained by total pelvic anterior-posterior (AP) excursion in sitting (41.5% of the variance, R2 = 0.415; p < 0.0001). Greater than 48% (R2 = 0.484) of the variance in TMT was explained by total pelvic AP excursion in walking (p <0.0001) and total thoracic medial-lateral (ML) excursion in standing (p < 0.0001), while greater than 26% (R2 = 0.262) of the variance in velocity was explained by peak thoracic excursion in the anterior direction in walking (p = 0.015) and total pelvic AP excursion in standing (p = 0.009). Thirty-one percent (R2 = 0.310) of the variance in double support percent, the portion of the gait cycle related to balance, was explained by total pelvic excursion ML in standing (p = 0.009) and peak thoracic excursion in the posterior direction in walking (p = 0.006). Conclusions: Trunk sway measures help explain impairments in gait, mobility, and falls in individuals with HD, and may represent a novel rehabilitation intervention in HD. An intriguing finding of this study was the association of increased fall risk with younger age. . We are conducting a study to determine its reliability and validity in the HD population. We present preliminary findings on the 1) interrater reliability, internal consistency, and 2) concurrent criterion validity of the STEPS tool with common balance and mobility tests. There were 14 participants (11 female, mean ± SD age 48.57 ± 11.32 years, mean ± SD Unified Huntington Disease Rating Scale (UHDRS) total motor score (TMS) 31.79 ± 20.34, mean ± SD total functional capacity (TFC) score 8.35 ± 3.39). Three trained clinicians (2 physical therapists, 1 nurse) rated each participant's performance negotiating a flight of 10 standardheight steps using the STEPS tool. The time to ascend and descend was measured using a stopwatch. 
Objective: To enhance estimates of Huntington disease (HD) progression using a simple and practical body sway assessment device (BTrackS™). Background: HD is a progressive neurodegenerative disorder with motor, cognitive, and psychiatric symptoms that typically emerge in the fourth or fifth decades. Balance assessments may be useful for predicting disease progression and fall risk, but studies are limited. Methods: We assessed total body sway (TBS) in 31 patients with HD and 24 normal controls (NC) using the BTrackS™ balance plate and laptop software. Subjects were administered a balance test consisting of 12, 10-s static balance trials that included combinations of eyes open or closed while standing on a stable versus unstable (i.e., foam) surface. A 1-way analysis of covariance adjusting for age was used in each condition to compare TBS. Correlations were assessed using Pearson's r. In addition, patients with HD were stratified with regard to fall risk on the basis of performance on the Timed Up and Go (TUG). Results: The patients with HD showed statistically significant TBS in all conditions (p = 0.000) compared with NC. When patients with HD were stratified with regard to fall risk on the basis of mean TUG score, those with greatest fall risk had statistically significant more TBS in most conditions (p = 0.008-0.04). TBS correlated most strongly with measures of motor ability (r = 0.501-0.614) and TFC (-0.358 to -0.461), as opposed to cognition (-0.109 to -0.281). Conclusions: Increased body sway and fall risk, easily evaluated using a brief balance assessment, may serve as important functional markers in patients with, and during the transition to, HD. Further studies will be needed to confirm and extend these findings. 
Background: There is increasing interest in inpatient physical rehabilitation programs for people with Huntington disease (HD). A 2-bed dedicated inpatient physical rehabilitation unit for people with HD was established at St Joseph's Hospital Sydney in 2010, serving our State with a population of 8 million. We aimed to review the clinical outcome for people admitted to this unit, during the first 2 years of operation.
Methods: We carried out a retrospective medical record review of consecutive people admitted to the unit. We used the change in Functional Independence Measure (FIM) score from admission to discharge, as the primary outcome measure. Results: We reviewed 50 medical records. FIM was missing for 3 people and 3 other people were admitted for reasons other than physical rehabilitation. Forty-one of 45 people had an improved FIM score upon discharge (average 14.3, SE 1.9). Twenty-eight percent of people were fully independent upon admission and discharge. Thirty-four percent of people improved in 2 or more functional categories (bed mobility, sitting, sit to stand, standing, transfers, indoor mobility, outdoor mobility, and stairs), and 38% did not. Sixty-five percent of the improvers improved in at least 4 functional categories. Conclusions: There is preliminary observational data to suggest inpatient rehabilitation can improve day-to-day motor function for people living with HD. 
Poster 14
Abstract
Background:
The Unified Huntington's Disease Rating Scale (UHDRS) is the principal means of assessing motor symptoms in Huntington disease (HD). However, these assessments are subjective and generally limited to episodic inperson visits. Wearable sensors can objectively measure motor features and could be of value in clinical research and care. Objective: To evaluate the feasibility of wearable sensors to measure the motor features of individuals with HD, prodromal HD, and controls without HD in clinic and at home. Methods: Thirty participants with manifest HD, prodromal HD, and controls will be enrolled and asked to wear 5 accelerometer-based BioStampRC sensors developed by MC10 on the chest and limbs for standardized in-clinic assessments and 2 days at home. Data collected from participants with HD will be compared with data from individuals without HD to identify abnormal movement and train algorithms. assessments of cognition (Stroop, Symbol Digit Modalities; total sum score was calculated by summing the total scores across these assessments) and motor functioning (chorea, dysarthria, and dysphagia items from the Unified Huntington Disease Rating Scale) were also collected. We examined item bias using differential item functioning (DIF) both across HD stage (prodromal, early, late) and relative to cognitive performance. We also examined correlations between self-report and associated clinician ratings. Three regression models were examined to determine the psychometric reliability of the PROs: a simple linear regression model, a heterogeneous variance model, and a heterogeneous variance model that examined total cognition. Results: Most PRO items were free from DIF for both staging and cognition. There were modest correlations between PROs and associated clinician report (range -0.40 to -0.60). Modeling analyses indicated that measurement breaks down as cognition declines and staging increases; psychometric reliability is compromised (i.e., split-half reliability < 0.80) when total cognition scores are < 136 for Chorea, < 109 for Speech Difficulties, and < 179 for Swallowing Difficulties. Conclusions: Our results indicate that the psychometric reliability of PROs does not consistently meet acceptable levels as HD symptoms progress and cognition declines. Clinicians should consider complementary assessments when total cognition scores exceed critical thresholds. For participants with limited cognitive impairment, PROs can provide reliable information about patient symptomatology. 
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Abstract
Objective: To examine the usefulness of a new behavioral questionnaire for patients with, and at risk for, Huntington disease (HD). Background: Behavioral changes, including apathy, depression, irritability, anxiety, and difficulty prioritizing and initiating activities, are characteristic features of HD. For families and caregivers, they are often the most distressing aspect of the disease. The assessment of these behavioral disturbances is therefore important. Methods: The University of California, San Diego (UCSD) HD-BQ was administered to 71 patients with HD, 46 at-risk, gene positive (AR+) patients, and 23 normal control (NC) subjects at our center. The UCSD HD-BQ was also administered to 41 HD caregivers. We used Cronbach's alpha analysis to examine the internal consistency of the HD-BQ components; 1-way analysis of variance/Tukey's post-hoc test to compare groups on dependent variables; and Pearson's product-moment correlations to compare HD-BQ scores with other variables. Results: The HD-BQ showed substantial internal consistency (Cronbach α = 0.94). It showed construct validity with high-tovery high correlations with other behavioral measures (Problem Behaviours Assessment (PBA-s) r = 0.60-0.64; Hospital Anxiety and Depression Scale (HADS) r = 0.75-0.79), and poor correlations with measures of cognitive functioning and motor impairment (r = -0.21 to 0.03 and -0.04 to 0.34, respectively). The HD-BQ discriminated between patients with HD (mean 30.4), pre-HD patients (mean 28.0), and control subjects (mean 6.6) (p = 0.000). When questionnaires were completed independently by 37 patients with HD/caregiver pairs, there was a discrepancy in the perception of impairment between patients and their caregivers, with caregivers identifying more behavioral changes (mean difference = 16.13 points). Items with the largest discrepancies included less insight with regard to symptoms, difficulty concentrating, difficulty initiating activities, loss of interest in previously enjoyed activities, and indecisiveness. Conclusions: The HD-BQ is a quick, reliable instrument for screening behavioral changes in patients with, and at risk for, HD. When possible, information regarding behavior should be corroborated by an informant as patients with HD tend to underestimate their impairment. Background: The CTiP, administered on a laptop, is a relatively simple and useful tool for evaluating the extent to which neurological conditions affect cognitive processing speed. It consists of three computerized reaction time (RT) subtests that progressively increase in task complexity: Simple RT (SRT); Choice RT (CRT), with an added decision component; and Semantic Search RT (SSRT) with an added conceptual component. Methods: Gene carriers (n = 77) were categorized using the Unified Huntington Disease Rating Scale total functional capacity and Penny Burden of Pathology score as early premanifest, transitional (i.e., individuals close to disease onset or with very mild HD), or moderate HD. Patients were administered the CTiP in addition to traditional cognitive assessments commonly used in HD. We also examined central processing speed using motor-corrected CRT and SSRT values. A 1-way analysis of covariance adjusting for age was used to compare group performance on the RT subtests. Results: The patients with moderate HD showed significantly slower reaction times in all conditions (p < 0.001) compared with NC. Importantly, even transitional patients showed significantly slower reaction times on the CRT (p < 0.01) and SSRT (p < 0.01), and in central cognitive processing, compared with NC. Conclusions: Our results suggest that the CTiP may be a useful and early marker of deficits in central cognitive processing in individuals with, and transitioning to, HD. The Everett Clinic, Everett, WA, USA.
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Abstract Aims: To improve the care of patients with agitation, anxiety, apathy, psychosis, and sleep disorders associated with Huntington disease (HD) by providing education and clinical management guidance. Methods: Over a 3-year period, a core subgroup of 9 research and clinical leaders from the behavioral working groups of the European Huntington Disease Network and Huntington Study Group developed guidelines for these 5 symptoms using an iterative process intended to be consistent with Institute of Medicine model. Owing to the limited evidence base we relied heavily on core group expert opinion for developing initial recommendation statements. Subsequently, a total of 110 statements were submitted via 5 web-based surveys to a broader group of 140 international experts who are primary investigators of the Enroll-HD clinical study.
Results: We sent the first round surveys to 140 email addresses, including all EHDN and HSG Enroll HD site investigators. A total of 83 recipients (40 EHDN, 43 HSG) answered at least 1 survey, with 74 completing all 5. We could not confirm how many recipients actually received the surveys. Of the initial 110 statements, 98 reached an agreement level of 85 %, the defined level for strong consensus. The level of agreement was similar across all 5 symptoms with strong consensus (86-94 %) depending on symptom. We sent the revised statements to the 83 people who responded to any first-round survey and got second-round responses from 55 recipients. All second-round statements reached the defined level of strong consensus. Next steps: Our poster will present 5 recommendation tables that will be included in an upcoming manuscript. Guidelines are intended as educational tools that provide options for management of each symptom as it presents in HD. 
Abstract
Objective: To present the hypothesis that perseveration, not just impulsivity, is a risk factor for suicide attempts in Huntington disease (HD). Background: The elevated incidence of suicide attempts in patients with HD is attributed to a variety of psychosocial and cognitive changes. Impulsivity, commonly defined as an action without foresight, is considered by many to be a cognitive risk factor for SA. Many patients with HD also experience perseverative thinking, an involuntary rumination, which can sporadically manifest with upsetting thoughts. Methods: Case series of 3 patients with HD who attempted suicide, where medical records, including patient accounts of motivation for suicide attempt, were reviewed. Results: We describe 3 female patients with manifest HD who attempted suicide. The mean age was 40 years, and all attempted suicide by overdosing on prescription medications. All noted a persistent rumination on personal stressors leading up to the attempts. Two of the patients "got stuck" on the belief that they were becoming too much of a burden to their families. The third persisted for several days on guilt over conflict in her marriage. In response to these experiences, each planned her overdose for days in advance. Conclusions: These 3 patients did not appear to act impulsively in their decisions to commit suicide. In each case, a thoughtful and deliberate plan was laid out as a result of perseveration on distressing thoughts. Further research is necessary to elucidate the relationship between perseverativeAbstract Introduction: Tetrabenazine (TBZ) is the only Food and Drug Administration-approved medication for the treatment of chorea related to Huntington disease (HD). TBZ carries a black-box warning for increased risk of depression and suicidal ideation, but these side effects are rarely observed clinically.
Methods: This was a retrospective, epidemiological study of the Enroll-HD database, designed to evaluate the severity of depressive symptoms between patients with motormanifest HD who were using TBZ (n = 300) versus those not using TBZ (n = 1930). These patients were further classified into subgroups based on their use of antidepressants. Baseline depression and suicidal ideation scores from the Problem Behaviors Assessment were compared between groups. Years since motor onset is a novel metric used to more accurately compare patients with motor-HD at different stages of their disease. Age and sex were also used as covariates. Abstract Background: The primary determinant of age of motor onset (AMO) for patients with Huntington disease (HD) is the number of CAG repeats within the HTT gene. However, environmental factors may also influence the disease course. Identification of these factors could provide strategies to delay disease onset. The aim of this study was to investigate the relationship between substances of abuse and AMO in patients with HD. Methods: This was a retrospective, epidemiological, observational study of the Enroll-HD database. Participants with motor-manifest HD (n = 2314) were considered for inclusion into 1 of 3 substance abuse groups: 1) tobacco abuse at baseline, 2) history of alcohol abuse in the past or at baseline, and 3) past or current use of drugs of abuse. A fourth group of participants that had never abused substances served as a control group. The primary outcome measure was the mean difference in AMO of participants in the substance abuse groups versus the control group, using CAG repeat length as a covariate. Results: The AMO was earlier for participants in the tobacco (n = 566), alcohol (n = 374), and drug-abuse groups (n = 217) than in the control group (n = 692) by 2. F(1, 909) = 29.7, p < 0.0001] years, respectively. In all substance abuse groups, the AMO was lowered to a greater degree in females than it was in males. Conclusions: Substances of abuse dramatically decreased the AMO in patients with HD. There are currently no diseasemodifying therapies available for patients with HD. However, these findings give providers a simple intervention to recommend to premotor manifest patients that could add years without motor symptoms to their lives.
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Registry: Status Update European Huntington's Disease Network, on behalf of Registry investigators and participants.
Abstract
Registry was initiated in 2004, and since 2013 sites and participants have been transitioning from Registry to Enroll-HD, the first global observational study on HD (www.enroll-hd. org), with around 50% of Registry sites now recruiting to Enroll-HD. It is the largest study of Huntington disease (HD) to date, and annually collects standardized clinical data and biospecimens on individuals affected by HD, HD family members, and controls. This observational, prospective, longitudinal, multinational, multicenter cohort study of HD demonstrates the successful collaboration of 161 expert HD clinical sites across 17 European countries. Over 13,000 participants have contributed clinical phenotypical data, with more than 10,000 participants additionally donating biosamples for use in large-scale genetic modifier and biomarker studies. Registry has been highly successful in establishing a wellcharacterized European-based HD cohort. The study has expedited implementation and recruitment for clinical trials and is an invaluable resource for clinical and genetic modifier studies. Registry data have been a solid basis for research, delivering more than 50 scientific publications. Key study metrics of the Registry cohort are summarized.
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Registry: Scientific Resource European Huntington's Disease Network, on behalf of Registry investigators and participants.
Abstracts
The European Huntington's disease Network's (EHDN) Registry study is an invaluable resource for scientists and researchers. Registry is a clinical research platform that can expedite experimental medicine studies, biomarker development, and refine clinical assessments for HD. Researchers can apply to use this high-quality, curated clinical data collected on more than 13,000 participants. In addition, more than 10,000 biosamples have been donated and there are 5 years of longitudinal data on 62% of participants. Registry core assessments comprise demographics, Unified Huntington Disease Rating Scale Motor, Function, and Behaviour, medical history, medication, comorbid conditions, HD clinical characteristics, local laboratory CAG repeat, and cognitive assessments, with additional clinical assessments and/or biosamples (blood and urine) collected as an optional extended battery. Access to the clinical database and to biosamples is regulated by the policies of EHDN (www.euro-hd. net/html/network/project/constitution/doc) and open to any scientist interested in HD research. University of Ulm, Ulm, Germany.
Abstract
Background: Clinical trials in Huntington disease (HD) are increasing in number and size, often competing for the same patients and clinical site resources. Enroll-HD is a clinical research platform that includes a prospective, longitudinal observational study of patients with HD as its core. Aims: To enhance the design and expedite the conduct of clinical trials in HD. Methods: Enroll-HD is active in over 135 HD clinical sites in North and South America, Europe, Australia, and New Zealand, with over 11,600 gene carriers, individuals at risk, and controls. Annual assessments include motor, cognitive and behavioral symptoms, demographic information, medical history, co-morbid conditions, and therapies. Research CAG repeat values are recorded. Informed consent includes an option to be contacted for possible future clinical research participation. Database searches produce listings of potentially eligible clinical trial participants. Regionally based specialist monitors or site managers with longstanding relationships with the sites are available to support clinical study teams. A developing clinical training portal will host modules relevant to HD clinical trials. Results: Support for 4 large global clinical trials included the selection of approximately 100 HD trial sites recruiting over 800 patients with HD and provided advice and troubleshooting for the project teams. Acknowledgements: Enroll-HD is a longitudinal observational study for HD families intended to accelerate progress towards therapeutics; it is sponsored by CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to developing therapeutics for HD. Enroll-HD would not be possible without the vital contribution of the research participants and their families. Objective: To describe the subset of patients with a cooccurrence of HD and MS within the ENROLL-HD database, and compare the prevalence of MS in the ENROLL-HD database to the prevalence of MS in the general population. Methods: 1) We described the characteristics of the subgroup of subjects with HD and MS. 2) We estimated the prevalence of MS in HD gene-positive participants and compared this prevalence to the MS prevalence in the general population (χ 2 test). Results: Of the subset of Enroll-HD participants with HD and MS (n = 8), the ratio of male to female patients was 2:6, and the most common HD reported symptoms were motor symptoms (n = 5), depression (n = 3), and irritability (n = 3). The mean ± SD age at inclusion was 43.13 ± 9.33 years, the mean ± SD age of onset of HD was 40.17 ± 9.58 years, and the mean CAG repeat number was 43 ± 3.92 [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] . Seven patients were on concurrent MS therapy and the diagnosis of MS was made before the diagnosis of HD in 4 patients (50%). From the 4146 patients included in Enroll-HD, 3176 were HD genepositive at the time of analysis. The prevalence of MS within the ENROLL-HD database was higher than the expected prevalence of MS within the general population (8/3176 = 0.0025 vs 100/100,000 = 0.001, p < 0.05).
Conclusions:
The descriptive analysis yielded an expected sex ratio and overlapping symptoms between MS and HD included motor symptoms, cognitive impairment, and depression. The prevalence of MS in patients with HD was higher than the expected prevalence of MS in the general population. Further analysis of longitudinal data will explore concurrent symptom progression of MS and HD. Results: There was no significant difference in sex or education between groups, but cases were younger than controls (mean ± SD age 41.0 ± 10.3 vs 43.7 ± 11.9 years; p < 0.005). All psychiatric scores were worse in the cases (all p <0.001). In MRI analyses, normalized volumes for striatal and limbic region structures were smaller in cases (all p < 0.01). Cortical regions (e.g., temporal, parietal, occipital, frontal, insular lobes) were also significantly smaller in cases. SCL-90R/ PSDI scores significantly predicted amygdala, frontal, and parietal imaging changes, and SCL-90R Depression scores predicted striatal and amygdalar volumes. There were no significant relationships between the other psychiatric scores and imaging measures. Conclusion: Gene-positive cases exhibit greater psychiatric symptoms than gene-negative controls. Changes in brain structures may already be detectable on MRI and may predict psychiatric issues in premanifest HD.
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Developing a Disease-Specific Health Index for Huntington Disease Steven Goldenthal, Elizabeth Luebbe, Molly Elson, Alistair Glidden, Ray Dorsey, and Chad Heatwole. University of Rochester, Rochester, NY, USA.
Methods: Blood was collected from healthy controls (n = 7) and individuals with HD (n = 9). IL-6 levels were measured in the plasma fraction following Percoll centrifugation, and PBMCs were stimulated with the inflammatory mediator CpG, or CpG plus an anti-IL-6 neutralizing antibody, to evaluate the role of IL-6 on metabolism of 2-AG. At the time of blood collection, UHDRS and TFC were conducted on participants with HD. Results: Plasma IL-6 levels were not different between controls and those with HD. CpG-induced production of IL-6 from PBMCs was similar in control and participants with HD, and was blocked by IL-6 neutralizing antibody. Metabolism of 2-AG from PBMCs treated with or without CpG were not different between healthy controls and individuals with HD. Correlation analysis comparing UHDRS TMS, total chorea score, or TFC with either plasma IL-6 levels, CPG-induced production of IL-6, or metabolism of 2-AG only demonstrated a correlation between plasma IL-6 and UHDRS TMS (r = -0.70). Conclusions: Lack of differences in baseline and CpGstimulated 2-AG metabolism suggests that elevations in IL-6 typically seen in blood of individuals with HD do not cause differential metabolism of the endocannabinoid 2-AG. 
Abstract
Huntington disease (HD) is a devastating neurodegenerative disease characterized by cognitive, psychiatric, and motor symptoms. Manganese (Mn) is an essential metal for all biological systems, as a co-factor for several biologically indispensable enzymes and activating other key cell-signaling pathways. Recently, a striatal neuronal deficit in Mn uptake has been observed in several HD models. Furthermore, this defect has been found to correspond to several enzymatic and cell-signaling defects observed in HD, including a Mn-dependent defect in Ataxia telangiectasia mutated (ATM)/p53 signaling. Interestingly, other critical cell-signaling pathways that are defective in HD [protein kinase B (AKT) and mammalian target of rapamycin] are also highly responsive to Mn levels. Treatment with insulin-like growth factor-1 (IGF-1), an upstream activator of AKT, has been shown to be neuroprotective in HD models. A proposed mechanism of neuroprotection is increased mitochondrial function and autophagy via upregulation of AKT and downstream pathways. In parallel, prior studies have shown that Mn can act as an insulin-mimetic, activating several of the same metabolic kinases and pathways that IGF/insulin activate. Our laboratory has discovered that Mn levels are increased with IGF-1 treatment in almost all cell lines tested. Furthermore, inhibition of PI3K, an upstream activator of AKT, can drastically reduce Mn uptake in a striatal cell line. These data suggest an intricate co-regulation between Mn homeostasis and IGF/insulin signaling, which will be further explored by rigorous pathway analysis. Also, given that Mn and IGF/insulin act on very similar pathways and both have been implicated in HD pathophysiology, we will test the hypothesis that a deranged co-regulation between IGF and Mn acts upstream of the AKT-dependent defects in mitochondrial function and autophagy in HD. In conclusion, we aim to elucidate IGF/Mn co-regulation in neuronal system in an effort to better understand their cellular consequences in HD pathology and provide potentially novel therapeutic targets. Results: RNA sequencing of the mouse striatum has identified 228 genes differentially expressed in WT animals after Mn exposure, while only 37 genes were significantly altered in HD mice after Mn treatment. Interestingly, 189 genes altered by Mn in mice with HD changed in a direction ameliorating the expression differences between WT and HD untreated animals. Pathway analysis suggests involvement of proinflammatory cytokine regulatory networks. Mn exposure of WT mice altered striatal genes associated with immune function and inflammatory response. Conclusions: Transcriptome analysis of the striatum suggests that HD mice are resistant to Mn-induced transcriptional changes observed in WT mice. These findings provide potential transcriptional and molecular targets to restore Mn homeostasis in HD. 
The course of Huntington disease (HD) can be divided into premanifest (no detectable or subtle signs and symptoms of HD) and manifest (unequivocal motor signs) period. Our previous study showed reduced corticostriatal functional connectivity at rest in subjects with prodromal HD (Unschuld et al. Neurosci Lett 2012), at 3 T. We therefore assessed functional connectivity in the premanifest and manifest period of HD by using functional magnetic resonance imaging (fMRI) at 7 T. Twelve patients with manifest HD [mean ± SD age 53 ± 12 years, mean ± SD CAG repeat 45 ± 5, mean ± SD Unified Huntington's Disease Rating Scale (UHDRS) motor score -9 ± 7, mean ± SD estimated years to symptom onset (YTO) 9± 8, according to Langbehn et al. Clin Genet 2004]; 10 patients in the premanifest period of HD with < 8 years before symptom onset (mean ± SD age 42 ± 10 years, mean ± SD CAG repeat 44 ± 3, mean ± SD UHDRS motor score 12 ± 10, mean ± SD YTO 4.2 ± 3); 12 patients in the premanifest period of HD with > 8 years before symptom onset (mean ± SD age 36 ± 10 years, mean ± SD CAG repeat 42 ± 3, mean ± SD UHDRS motor score 3 ± 5, mean ± SD YTO 20 ± 10); and 16 healthy controls (mean ± SD age 44 ± 14 years) were studied. The functional connectivity between the striatum and several cortical areas were analysis. Two tailed t test was applied. Functional connectivity between striatum and premotor area, supplementary motor area, inferior frontal, and mid-frontal region were impaired comparing all patients with manifest HD with controls, and each of the two premanifest HD groups with controls (all p-values < 0.05). These data indicate impaired functional connectivity between motor areas, as well as other frontal areas and striatum in the premanifest period and the manifest period of HD, consistent with our previous data at 3 T. The data indicate an impairment of corticostriatal connections in patients who are even more than 8 years before estimated motor signs onset. This may be a useful marker for future clinical trials. Abstract Huntingtin (HTT) is the large product (350 kD) of the HTT gene with the CAG repeat. The expansion of the CAG repeat causes the polyglutamine (polyQ)-expanded HTT, which is responsible for 1 of the dominant inherited autosomal diseases, Huntington disease (HD). Wild-type HTT contains 6 to 35 glutamine residues, and proteins containing > 35 glutamine residues cause HD. Prevalence of HD is 4 to 10 cases per 100,000 in Western European and it varies by culture. Patients with HD suffer from adult-onset chorea (involuntary movement), and cognitive and psychiatric decline. HD affects medium spiny striatal neurons in the early stage and entire brain in the late stage. HTT is a multidomain protein. The polymorphic glutamine/proline (Q/P) domain lies at the N-terminal region, and downstream of the polyQ/P domain, HTT, elongation factor 3, protein phosphatase 2Am and yeast kinase TOR1 repeats are found. We revealed that HTT has overall spherical structure by three-dimensional (3D) electron microscopy (EM) analysis. 3D EM structure and cross-linking mass spectrometry analysis showed there is no substantial difference between 23Q-HTT and 78Q-HTT. However, circular dichroism analysis revealed α-helical structure modification as polyQ size increases. We examined the effect of polyQ size change on post-translational modification, and 2 novel phosphorylation sites were revealed. Also, the phosphorylation status distinguished HTT with different polyQ size. Removal of phosphoryl group of 78Q-HTT dramatically affects the level of polycomb repressive complex 2-stimulating activity compared with 23Q-HTT. in the first decades of the nineteenth century. Families have traced their HD history back to transported convicts and free settlers to the new British colony. The year 1902 saw the first description of the disease in the Australian medical literature-2 brothers had been admitted to an asylum in Sydney. The author, Dr. Charles Hogg, was born in an area of Tasmania with many HD families. His grandfather was the local doctor-like George Huntington, his early exposure likely aided his recognition of this previously hidden disease. Also born in Tasmania, and acquainted with HD families, Dr. Charles Brothers published a survey in 1949. This led to Tasmania recording the highest prevalence of HD in the world, prior to the discovery of the Venezuelan kindred. The eugenics movement played its role in the Australian HD story. Journal articles on HD included sections on eugenics, and Brothers wrote a paper titled "Psychiatry and Eugenics", which prominently featured HD. Newspapers and educational societies frequently called on the "unfit" with "hereditary disease" to be sterilized or prohibited from having children. This contributed to the stigma, shame, and secrecy that were such prominent features of living with the disease. Isolated families managed HD with little help. The 1970s saw the beginning of changes-a team of researchers began addressing the needs of families, with the first Australian HD Association being formed in 1973 in the state of Victoria, followed soon by other states. HD was finally coming out of the closet.
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Attitudes Towards Gene Therapy in Huntington Disease Tanya M. Bardakjian and Pedro Gonzalez-Alegre. Hospital of University of Pennsylvania, Philadelphia, PA, USA.
Abstract
Background: Gene therapy research is aimed at optimizing delivery methods for gene therapy agents that are safe and effective. It is important to identify the attitudes of, as well as their acceptance of, certain risks and modalities, in order to improve the feasibility of trials. The goal of this study is to identify the threshold of risk for willing participants and those who decline to participate in clinical trials, and respondents' concerns about participating. Methods: A survey consisting of mainly Likert scale responses was utilized and sent through the Huntington's Disease Society of America's online portal/website and was only available for 21 days at this submission. Data: There were 45 responses from individuals at risk for Huntington disease (HD) or with HD. In total, 45% answered that they are very likely to participate in gene therapy trials. However, this number dropped to 26% when asked if they would participate if the treatment required a brain injection. Twenty-six percent were very likely if the gene therapy had a high chance of improvement with a high risk of side effects. Fifty-nine percent replied that they were very likely to participate if the treatment was to cure their HD versus 61% if it was to slow the progression. Forty-nine percent were willing to participate only to help future generations. Only 23% were very likely to participate in gene therapy if a placebo would be used as part of the trial design. Thirty-six percent of participants were very likely to participate if they did not have HD symptoms yet versus 48% if they had started to show minimal symptoms. Conclusion: Individuals at risk for HD or who have a diagnosis of HD have varied thresholds for risk acceptance based on disease state, treatment modality, and potential clinical benefit. Data will continue to be collected to help delineate these differences. Abstract Background: Huntington disease (HD) is a progressive autosomal dominant genetic disorder characterized by variable motor, cognitive, and psychiatric symptoms. The mean age of onset is 35 to 44 years [1] . Clinical expression is associated with a trinucleotide repeat expansion, 36 or more CAG trinucleotide repeats in the HTT gene on chromosome 4. Case history: A 39-year-old white woman with apparent HD was referred to our clinic for diagnosis and treatment. It was reported that she experienced onset of psychiatric symptoms in her early 30s and chorea at the age of 35 years. There was no family history of HD in a sibship of 15 individuals, 5 older than her. DNA testing revealed CAG repeat alleles of 47 and 24, consistent with the clinical diagnosis of HD. The proband's parents were DNA tested and her 72-year-old asymptomatic father had alleles of 32/17 and her 65-year-old mother had CAG repeat alleles of 24/15. Two of the proband's siblings underwent DNA testing and were found to have the normal paternal allele. Conclusion: These data support the hypothesis that the paternal intermediate allele (IA) of 32 CAG repeats, a moderaterisk allele for disease causing expansion in offspring [2] , was expanded to an unprecedented number in the fertilization event involving our patient. Genetic counseling and DNA testing for "at-risk" offspring is ongoing with 2 normal DNA results of 17/15 having been reported in 2 of the siblings. DNA testing on paternal buccal cells is ongoing to rule out somatic mosaicism. Clinical and psychological evaluation of the IA carrier is in progress. 
Background: Driving, a vital activity for many people, requires multiple cognitive abilities. While impaired cognition has a negative effect on driving performance, > 30% of people with dementia continue to drive. There is a key deficiency in assessment standards among professionals to manage risk of dementia-impaired driving. Methods: Community professionals and members of the National Association of Social Workers (NASW) in a northeast state were asked about their assessment process for driving competency in people with dementia. Community professionals were individually interviewed and findings were developed into themes. NASW members were emailed a survey that included Likert-style, dichotomous, and open-ended questions. Quantitative responses of those who work with people who have dementia were analyzed and responses to open-ended questions were developed into themes. Results: Individual interviewees from the community identified issues and barriers, as well as proposed solutions to help professionals discuss driving cessation with patients who have dementia. Results from the NASW survey were analyzed using bivariate correlation. Three significant correlations were found: number of years in practice and likelihood of discussing driving cessation; perceiving barriers to addressing driving cessation and difficulty discussing driving cessation; and sufficient training and comfort level with discussing driving cessation with patients. All of the survey responders who worked with patients who had dementia (n = 53) and responded to the question,"Do you believe that guidelines to address driving cessation with clients who have dementia and their families would be helpful to the field?" indicated that they strongly agreed or agreed. Conclusions: Based on the results of this small study, appropriate guidelines and training would benefit both community professionals and social workers in addressing driving competency with people who have dementia. Next steps include the creation of a brief guide outlining a comprehensive action plan to improve the overall evaluation and management of dementia-impaired driving.
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Quality Improvement in Healthcare for Huntington Disease Mary C. Edmondson, Charlene Hudson, Katie LeeginsVinson, and Ann Lassiter. HD Reach, Raleigh, NC, USA.
Abstract
Improving patient outcomes in Huntington disease (HD) requires the design of effective processes to deliver existing treatments. Quality improvement (QI) initiatives seek to improve patient outcomes by streamlining care processes, reducing treatment barriers, and educating providers. In order to better understand how care is provided to patients with HD in North Carolina, HD Reach instituted a QI project utilizing the Six Sigma "DMAIC" process. Phase 1 of the process included review of consecutive clinical encounters to identify care factors, including client type, presenting problem, intervention provided, complexity, and provider effort. Data were reviewed with clinical staff to improve patient care and training on a regular basis. Job aids, documentation templates, and assessment tools were developed from staff feedback. Treatment impact measurement based on goal attainment scaling is in the early testing stage. Phase 2 of the QI project involved the implementation of needs assessment surveys of the HD family community and NC providers highly experienced in HD care. The surveys revealed specific needs for improvement in provision of long-term care and access to psychiatric services and genetic counseling. The surveys confirmed that distance to clinic, cost of care, work-caregiving schedules, and hopelessness about effective treatments prevent people with HD from receiving the full spectrum of care. Phase 3 of the QI project will undertake a "DMADV" design process to create patient-centric care processes involving the subspecialty clinic, the community provider, care management, technology solutions, and the HD family. QI efforts are a valuable method to determine where efforts are most needed to support patients, families, and care providers across the care continuum. Additionally, the QI process creates a structure for improvement that is strategic, continuous, and sustainable.
